Altogether, such findings indicate oncogenic overexpression of FGFR as an additional signaling pathway to induce aberrant STAT3 activation in tumor cells and suggest therapeutic strategies to treat FGFR-overexpressing cancers. Here, STAT3 is linked to neoplasm.